SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 76.24 |
| Enterprise Value ($M) | -22.63 |
| Book Value ($M) | 5.89 |
| Book Value / Share | 0.05 |
| Price / Book | 12.94 |
| NCAV ($M) | 3.93 |
| NCAV / Share | 0.03 |
| Price / NCAV | 19.40 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -23.82 |
| Return on Assets (ROA) | -3.42 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.06 |
| Current Ratio | 1.06 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 104.60 |
| Assets | 106.57 |
| Liabilities | 100.67 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.99 | 47.96 | |
| 13G/A | Vestal Point Capital, LP | 1.00 | -72.44 | |
| 13G/A | Janus Henderson Group Plc | 9.20 | 64.34 | |
| 13G/A | Alyeska Investment Group, L.P. | 4.20 | -35.43 | |
| 13G/A | Perceptive Advisors Llc | 8.50 | 118.44 | |
| 13G/A | Alexandria Real Estate Equities, Inc. | 10.30 | -2.33 | |
| 13G | BlackRock, Inc. | 6.00 | 0.00 | |
| 13G | Morgan Stanley | 8.60 | ||
| 13D/A | Shendelman Shoshana | 6.60 | -9.76 | |
| 13G/A | Propel Bio Management, LLC | 10.50 | 69.66 | |
| 13G/A | Orbimed Advisors Llc | 0.00 | -100.00 | |
| 13G/A | Armistice Capital, Llc | 0.00 | -100.00 | |
| 13G/A | Fmr Llc | 3.14 | -18.33 | |
| 13G/A | Franklin Resources Inc | 9.99 | -0.98 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,089,220 | 3,312,368 | 32.88 | |
| 2,610,221 | 6,851,070 | 38.10 | |
| 1,897,538 | 5,718,353 | 33.18 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALT – Altimmune, Inc. | ANIP – ANI Pharmaceuticals, Inc. |
| APGE – Apogee Therapeutics, Inc. | AQST – Aquestive Therapeutics, Inc. |
| ARCT – Arcturus Therapeutics Holdings Inc. |
Financial data and stock pages provided by
Fintel.io